Adverse Events and Serological Responses After SARS-CoV-2 Vaccination in Individuals With Inflammatory Bowel Disease

INTRODUCTION: We determined adverse events after 4 doses of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), and risk of IBD flare. METHODS: Individuals with IBD we...

Descripción completa

Detalles Bibliográficos
Autores principales: Markovinović, Ante, Quan, Joshua, Herauf, Michelle, Hracs, Lindsay, Windsor, Joseph W., Sharifi, Nastaran, Coward, Stephanie, Caplan, Léa, Gorospe, Julia, Ernest-Suarez, Kenneth, Ma, Christopher, Panaccione, Remo, Ingram, Richard J.M., Kanji, Jamil N., Tipples, Graham, Holodinsky, Jessalyn K., Bernstein, Charles N., Mahoney, Douglas J., Bernatsky, Sasha, Benchimol, Eric I., Kaplan, Gilaad G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2023
Materias:
Brief Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10453345/
https://www.ncbi.nlm.nih.gov/pubmed/37216598
http://dx.doi.org/10.14309/ajg.0000000000002337
Descripción
Sumario:INTRODUCTION: We determined adverse events after 4 doses of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine in those with inflammatory bowel disease (IBD), associations between antibodies and injection site reactions (ISR), and risk of IBD flare. METHODS: Individuals with IBD were interviewed for adverse events to SARS-CoV-2 vaccine. Multivariable linear regression assessed the association between antibody titers and ISR. RESULTS: Severe adverse events occurred in 0.03%. ISR were significantly associated with antibody levels after the fourth dose (geometric mean ratio = 2.56; 95% confidence interval 1.18–5.57). No cases of IBD flare occurred. DISCUSSION: SARS-CoV-2 vaccines are safe for those with IBD. ISR after the fourth dose may indicate increased antibodies.

Ejemplares similares